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Introduction
Living things undergo aging process over time. This 
is nature. During the process of natural senescence,
alterations in the genetic signals dictate the direction,
the rate, and the consequences of aging. Aging process
also occurs in the mitochondrial genome. The genetic
components of human mitochondria lie within the
circular structure of the mitochondrial DNA (mtDNA)
within the mitochondria itself1,2. However, interactions
of nuclear DNA (nDNA) and mtDNA dictate the integrity
of the structural and functional proteins of mitochon-
drial machinery and cells. Lack of histone protection
and low efficiency of mtDNA repair render mtDNA more
susceptible than nDNA to “genetic error” (mutation). As
a consequence, mutated mtDNA or nDNA causes alter-
ations in mitochondrial functions, one of which is de-
rangement of oxidative phosphorylation (OXPHOS) and
cellular energy failure. Disorders of OXPHOS3,4 and mito-
chondrial disease (MtD)5–7 are 2 common names used
interchangeably for “mitochondrial cytopathy”8. There-
fore, knowing the molecular basis of mitochondria,
interaction between nDNA and mitochondria, and re-
cognition of the variety of phenotypes of MtD are im-
portant steps to the understanding of mitochondrial
medicine.
Awareness of the Molecular Basis and
Clinical Manifestations of MtD
Aberration from the normal functions of mitochon-
drial respiratory chain or OXPHOS causes disorders
that involve multiple organs, such as the brain, ears,
endocrine systems, eyes, heart, kidneys, liver, muscles,
peripheral nerves, and skin. Normal functions of the
mitochondrial respiratory systems are dictated by the
integrity of both nDNA and mtDNA. Direct hits of either
the mutation of mtDNA itself or nDNA may cause de-
fects in cellular or mitochondrial OXPHOS. Two forms of
mtDNA mutations are recognized9. They are: (1) mtDNA
mutations that interfere with mitochondrial protein
synthesis; and (2) mtDNA mutations that impair specific
protein-encoding genes, and thus mitochondrial protein
transport10. In contrast, there are 3 patterns of nDNA
mutations that affect the mitochondrial respiratory
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chain. They are: (1) nDNA gene mutations that encode
subunits of respiratory chain complexes such as com-
plexes I and II; (2) nDNA mutations that interfere with
the genes encoding ancillary proteins needed for correct
assembly and function of the respiratory chains such
as complexes III, IV, and V; and (3) nDNA mutations that
interrupt intergenomic signaling and thus the quality
of mtDNA. The “double hits” theory may apply to the
latter. Regardless of the mechanism, the final conse-
quence would be derangement of cellular OXPHOS,
which manifests clinically as MtD. More than a dozen
clinical syndromes of MtD have been recognized11 and
they are collectively called the syndromic MtD/OXPHOS
disease. Recognition of the manifestations of syndromic
MtD is of utmost importance to the diagnosis of the
majority of MtD.
Characteristics of Syndromic MtD
1. Chronic progressive external ophthalmoplegia
(CPEO)12,13 manifests by chronic insidious onset of
bilateral ophthalmoparesis (Figure 1C) with or
without familial occurrence. CPEO can be misdiag-
nosed as ocular myasthenia gravis or other forms
of congenital ocular myopathy. The lack of diurnal
change of weakness, and disproportionate paraly-
sis of the extraocular muscles and levator palpe-
brae are the key features to distinguish CPEO from
myasthenia gravis. Diabetes mellitus (DM) is a com-
mon association in Taiwanese patients with CPEO
and A3243G genotype14,15. However, A3243G geno-
type may have diverse clinical phenotypes16. In
essence, mtDNA rearrangement, deletion, and single
point substitution are common molecular mecha-
nisms of CPEO16–18.
2. Kearns-Sayre syndrome (KSS)19–21 has onset of symp-
toms at childhood or adolescence. The clinical mani-
festations are ocular symptoms and signs of CPEO
with pigmentary retinopathy, such as retinitis pig-
mentosa (Figure 2), ataxia with cerebellar atrophy,
dementia or mental retardation, short stature, deaf-
ness, cardiac arrhythmia, multiple endocrine disor-
ders, and myopathy. Lactic acidosis and cerebral
white matter lesions22 may occur. The diagnostic
criteria are progressive external ophthalmoplegia,
A B
C
Figure 1. (A, B) Magnetic resonance imaging (T2WI) of a young man with mitochondrial myopathy, encephalopathy, lactic
acidosis, stroke-like episodes phenotype and A3243G genotype, (C) whose mother shows a chronic slowly progressive exter-
nal ophthalmoplegia (CPEO) phenotype with bilateral blepharoptosis and A3243G genotype (CPEO/A3243G).
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pigmentary retinopathy, and one of the 3 other
features such as complete heart block, cerebrospinal
fluid protein >100 mg/dL, and ataxia. Phenotypic
mimicry has been reported in KSS and Lowe syn-
drome23. The prognosis is poor. MtDNA deletion18,24
occurs in more than 70% of patients with KSS.
Approximately 99% of mitochondrial deletions occur
within the common area between nucleotide posi-
tions (np) 5,000 and 16,000. Deletions are of differ-
ent sizes in different people5. Rapidly dividing cells
lose the deleted mitochondria over time. A sporadic
somatic cell mutation (germ line is normal), mito-
chondrial duplication, and single point mutation at
tRNALeu have also been reported25.
3. Leber’s hereditary optic neuropathy (LHON) is the
most frequent cause of maternally inherited, pain-
less, bilateral blindness that occurs in young
adults11. Pattern reversal visual evoked potentials
(VEP) confirm the severity of the optic neuropathy
(Figure 3). Movement disorders, dementia, and 
cardiomyopathy may occur26. Cerebral white mat-
ter changes resemble multiple scleroses27. It is 
estimated that 75–95% of LHON are caused by
mutations of G11778A (40–60%) and G3460A (20%)
that affect complex I, and G15257A (15%) that
affect complex III. At least 8 major mutations have
been recognized11.
4. Mitochondrial myopathy, encephalopathy, lactic
acidosis, stroke-like episodes (MELAS) syndrome28,29
is the most common syndromic manifestation of
MtD that occurs in all age groups. The clinical course
of MELAS is slowly progressive with stepwise deteri-
oration. The severity of lactic acidosis correlates
with the severity of neurologic deficit30. Epilepsy is
frequent in patients with MELAS. Epilepsia partialis
continua or Koshevnikov syndrome may occur31.
Calcification of bilateral basal ganglia32, ischemic
stroke-like lesions (Figure 1A and B) involving the
posterior temporal and parieto-occipital lobes cross-
ing 2 or more arterial territories, and deep white
matter changes in watershed areas and subcortical
regions are common in patients with MELAS33.
Brain single-photon emission computed tomogra-
phy (SPECT) shows focal hyperperfusion (hyperemia)34
or regional hypoperfusion35 at different stages of
the disease. Reversible vasogenic edema, focal brain
Figure 2. Photograph of eye fundus of a patient with
Kearns-Sayre syndrome shows retinitis pigmentosa (courtesy
of Dr YS Chen, CGH, 1997).
BA
Figure 3. Pattern reversal visual evoked potentials (VEP) of a patient with Leber’s hereditary optic neuropathy. (A) Remarkable
delay in P100 latency with poor waveform and decreased amplitude of the VEP following left eye stimulations. (B) Absence
of all visually evoked responses in the right eye.
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ischemia or “mitochondrial vasculopathy”35,36, neu-
ronal metabolic derangement, and cellular energy
failure have been accrued to the characteristic
lesions seen on brain magnetic resonance imaging
(MRI). Cortical atrophy with dementia is a late con-
sequence of MELAS. A-to-G transition of tRNALeu (UUR)
gene at np 3243 is the most frequent mutation
(>90% of patients) found in both Caucasians and
Orientals with MELAS (MELAS/A3243G)37–43.
5. The syndrome of myoclonic epilepsy and ragged red
fibers (MERRF)41,44 occur more often in children and
young adults. Photosensitive myoclonus, myopathy,
and epilepsy are cardinal features. Myopathy occurs
in 70% of patients carrying the A8344G mutation41.
Ataxia may occur in 50% of patients. Short stature,
optic neuropathy, and lipomata are uncommon asso-
ciations. A8344G mutation in the tRNAlys gene occurs
in 80–90% of patients with MERRF41,45,46. T-to-C
transition at np 8356 (T8356C) in the tRNAlys gene47
and point mutation in the tRNASer gene46 have also
been reported.
6. Maternally inherited myopathy and cardiomyopa-
thy syndrome occurs in A3260G in tRNAleu and
T3250C in tRNAleu48. Under very rare circum-
stances, dual mutations with 3,399 large-scale dele-
tion and T5814C substitution49 may present with 
a clinical syndrome of oculopharyngeal somatic
myopathy. Further, patients with MtD may develop
neuropathy with ataxia and retinitis pigmentosa
(NARP). T8993G (leu to arg) and mutation at ATPase
subunit 6 (complex V) have been accrued to cause
NARP50.
7. Overlap syndromes of MtD have been reported. They
are LHON/MELAS overlap syndrome with G13513A
mutation51, MERRF/MELAS with A3243G overlap
syndrome52, CPEO/MELAS overlap syndrome53, and
CPPDM3243/MELASDM324315.
8. Polyneuropathy, ophthalmoplegia, leukoencepha-
lopathy, and intestinal pseudo-obstruction (POLIP),
also known as mitochondrial neurogastrointestinal
encephalomyopathy, is characterized by dysmotility
and paresis of the gastrointestinal tract, episodic
vomiting, and progressive malnutrition that may
lead to death in early or middle age life54. Post-
mortem pathologic studies showed neuronal loss
of the celiac ganglion, fibrosis of the mesenteric and
Auerbach plexuses, and leukoencephalopathy54,55.
Multiple mtDNA deletion is one of the causes of
POLIP56.
Nonsyndromic Manifestations of
Mitochondrial Disease (NSMMtD)
OXPHOS diseases may present with a number of
NSMMtD ranging from an isolated neurologic symptom
or sign to various combinations with non-neurologic
features. Movement disorders manifested by chorea,
tremor, hemiballism, ataxia, or dystonia, migraine-
like headache, neuropsychiatric manifestations, and
endocrine disorders such as hypopituitarism, defi-
ciency of secretion of antidiuretic hormone, hypogo-
nadism, and DM are common combinations. Some
other features of central nervous system manifesta-
tions may be secondary to organ failure such as hepatic
encephalopathy and nephropathy.
Work-up of Suspected MtD
The work-up of suspected MtD, in the order of increasing
strength of evidence and difficulty of the techniques
and their invasiveness, are listed below.
1. As MtD is notoriously caused by maternal inheri-
tance of a variety of mtDNA mutations, obtaining 
a detailed family history and pedigree of the index
case is of utmost importance. Specific attention must
be paid to the family history of a wide range of
symptomatology, such as visual disturbance, hear-
ing deficit, migraine-like headache, early onset of
stroke-like episodes, familial occurrence of epilepsy,
involuntary movements, symptoms suggestive of
myopathy or recurrent myoglobinuria, exercise intol-
erance, unexplained endocrine disorders and renal
dysfunction, familial occurrence of early-onset DM,
thyroid disorders, etc.
2. Blood tests must include plasma levels of glucose,
lactate and pyruvate ratio, creatinine phosphokinase,
liver and renal function tests, etc. Following informed
consent, collection of mtDNA from among the fam-
ily members, especially from siblings and maternal
relatives, is a key step to the molecular diagnosis.
Searching for common mtDNA mutations, such as
mtDNA rearrangement, mtDNA deletion, mitochon-
drial duplication, or point mutation, can be labori-
ous. Determination of heteroplasmy, mosaicism, and
mutant load is critical for explaining the heterogene-
ity of phenotype-genotype correlation57–60. Moreover,
the mtDNA mutation loads are selectively amplified
through generations60 and aging57.
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3. Work-up of the specific organ systems depend on
the degree of suspicion of the syndromes which
the index case may have. Examinations of the eye
ground for retinitis pigmentosa, optic atrophy, and
cataract. Evaluations of the auditory systems, gas-
trointestinal systems, kidneys, endocrine systems,
central and peripheral nervous systems, neuromus-
cular systems, and cerebrospinal fluid examina-
tions, etc. must be individualized. The extent of
examinations depends on the specific syndromes
suspected.
4. Neuroimaging and electrophysiologic studies 
include brain MRI32,33,61, and brain SPECT for those
with epilepsy, dementia, and stroke-like episodes34,35.
Magnetic resonance spectroscopy and positron
emission tomography are used for the evaluation
of regional brain metabolism, electroencepha-
lography for seizure evaluation, VEP for objective
assessment of the optic pathways, and nerve con-
duction studies for quantification of peripheral
nerve involvement.
5. Muscle biopsy with a rapid modified Gomori-
trichrome stain looking for the presence of “ragged
red fibers” (RRF) is the classical standard proce-
dure62. An immunohistochemical stain can be very
helpful for assessment of the severity of respi-
ratory enzyme deficiency and molecular diagno-
sis. A deficiency of coenzyme Q10 in the muscle,
but not in blood, has been reported63. Oral sup-
plementation of coenzyme Q10 ameliorated dra-
matically clinical symptoms63. Moreover, electron
microscopic examinations of the skeletal muscles
may provide additional evidence of mitochon-
drial disorders when a light microscopic exami-
nation of the muscle tissues fails to show typical
characteristics of RRF on modified Gomori-
trichrome stain.
6. Molecular diagnosis must include the whole mito-
chondrial genomic screening of the different tissues.
The mutant load and mosaicism of mitochondrial
mutations will determine the phenotypes of the
patients. Mitochondrial genomic DNA from muscle
tissue, peripheral white blood cells, and hair folli-
cles are samples most often examined in patients
suspected to have MtD and in screening for sub-
clinical cases or unaffected family members. The 
percentage of mutant load of different tissues 
can be determined that correlate with the clinical
manifestation41.
Pathologic Changes of MtD
The histopathologic characteristics of MtD have been
well studied in skeletal muscle. Three aspects of assess-
ment include light microscopic findings, electron micro-
scopic findings, and molecular diagnosis.
Light microscopic findings
1. The histopathologic finding of RRF of skeletal mus-
cles on modified Gomori-trichrome histochemical
stain62 is a hallmark of mitochondrial disorders.
The mitochondrial dysfunctions could lie within
the respiratory chain or outside it. Examples of
some conditions of primary MtD due to defects
outside the respiratory chain are carnitine palmi-
toyl transferase, pyruvate dehydrogenase complex,
beta-oxidation, or fumarase deficiencies. Conversely,
in some types of defects of the respiratory chain,
RRF are not seen15,31. Examples are cytochrome 
c oxidase (COX) deficiency in Leigh’s syndrome, and
Kojewnikoff syndrome with MELAS31. Supplemen-
tation of coenzyme Q10 may be helpful either in
familial mitochondrial encephalomyopathy with
coenzyme Q deficiency or in patients with Leigh’s
disease63,64. Furthermore, RRF and ultrastructural
changes of mitochondria are also seen in non-
MtDs6,65,66. The ultrastructural alterations of mito-
chondria in the skeletal muscles of patients with
MtD/OXPHOS disease were elucidated in the papers
of Shy and Gonatas and Shy et al., and were de-
scribed as “giant mitochondria”, “pleoconial myo-
pathy”, and “megaconial myopathy” in 1964 and
1966, respectively67,68.
2. Abnormal histochemical stains for mitochon-
drial enzymes such as succinate dehydrogenase,
NADH-tetrazolium reductase, COX, etc. can be
semiquantified.
Electron microscopic findings
1. Megaconial myopathy (enlarged mitochondria with
disoriented cristae)67,68.
2. Pleoconial myopathy (abnormal proliferation of
normal-looking mitochondria)68.
3. Intramitochondrial “paracrystalline” inclusions or
osmiophilic inclusions. There are 2 types of crystal-
line inclusions in MtDs: (a) typical type 1 paracrys-
talline inclusions with “parking lot” appearance
(Figure 4), usually found in the intracristal spaces;
and (b) type 2 large rectangular crystalloid inclusions,
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which are usually found between the inner and
outer mitochondrial membranes7. Paracrystalline
inclusions may also be seen in normal human
muscle, in patients with neuromuscular disorders
other than primary MtD, such as in zidovudin myo-
pathy65, muscle ischemia66, and in certain condi-
tions caused by mitochondrial toxins such as the
uncoupling agent 2,4-dinitrophenol. The nature
and origin of these inclusions remain unclear. They
are composed of proteins that are enzymatically
inert69, but may be immunoreactive to mitochon-
drial creatine kinase.
4. Abnormally branched and distorted cristae, con-
centrically arranged cristae, flattened cristae periph-
erally, or straight transverse cristae.
5. Mitochondrial matrix may appear empty or vacuo-
lated or contain osmiophilic or other electron-dense
bodies. Rarely, the electron-dense bodies consist of
amorphous or granular inclusion, which are rich in
iron10.
6. “Needle-like” crystal inclusions (Figure 5) in the mito-
chondria with deformed mitochondrial crista31.
In essence, understanding of the current concepts
of mitochondrial medicine is a milestone in the diag-
nosis and management of patients with MtD.
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